Scholarlink

Background <p>Roxadustat, a prolyl hydroxylase domain inhibitor that stabilizes hypoxia-inducible factor (HIF) expression, is a recently developed drug for the treatment of renal anemia. Studies have shown that HIF activation not only stimulates the production of endogenous erythropoietin but also modulates bone metabolism. Patients with chronic kidney disease (CKD) often present with abnormalities in bone metabolism in addition to concomitant anemia. However, the effect of Roxadustat on bone metabolism markers in patients with renal anemia have rarely been reported.</p> Objective <p>(1) To investigate the effect of Roxadustat on bone metabolism markers in patients with renal anemia; (2) To investigate the effect of Roxadustat on inflammatory and lipid metabolism markers in patients with renal anemia.</p> Methods <p>This retrospective observational study enrolled a total of 52 patients with anemia secondary to CKD, who were categorized into a roxadustat group and a control group based on whether they received roxadustat treatment. The following markers, including hemoglobin (Hb), β-C-terminal telopeptide of type I collagen (β-CTX), total type I procollagen intact N-terminal propeptide (tP1NP), parathyroid hormone (PTH), osteocalcin (OC), 25-hydroxyvitamin D (25-OHD), alkaline phosphatase (ALP), calcium (Ca), and phosphorus (P), C-reactive protein (CRP), Procalcitonin (PCT), total cholesterol (TC), low-density lipoprotein (LDL), were measured before and after treatment. The changes of bone metabolism, inflammatory and lipid metabolism markers were compared before and after treatment.</p> Results <p>After a period of Roxadustat treatment, β-CTX and PTH levels were significantly lower compared to pre-treatment, while tP1NP, 25-OHD, and ALP levels increased compared to pre-treatment (<i>P</i> &lt; 0.05). Inflammatory markers (PCT) and lipid metabolism markers (TC, LDL) were significantly reduced (<i>P</i> &lt; 0.05). No statistically significant differences were observed in the control group.</p> Conclusion <p>In this study, Roxadustat treatment for renal anemia was associated with simultaneous improvements in markers of bone metabolism, inflammation, and lipid metabolism in CKD patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of Roxadustat on bone metabolism markers in patients with renal anemia

  • 期刊论文

  • 发表日期：

    2025年12月29日

查看全文
  • Jianglin Yu,
  • Zhijie Lei,
  • Yaxin Chen,
  • Rui Yao,
  • Xiaoyang Qi,
  • Xiang Li,
  • Yixin Chen,
  • Wei Zhu,
  • Xusheng Qiu

摘要

Background

Roxadustat, a prolyl hydroxylase domain inhibitor that stabilizes hypoxia-inducible factor (HIF) expression, is a recently developed drug for the treatment of renal anemia. Studies have shown that HIF activation not only stimulates the production of endogenous erythropoietin but also modulates bone metabolism. Patients with chronic kidney disease (CKD) often present with abnormalities in bone metabolism in addition to concomitant anemia. However, the effect of Roxadustat on bone metabolism markers in patients with renal anemia have rarely been reported.

Objective

(1) To investigate the effect of Roxadustat on bone metabolism markers in patients with renal anemia; (2) To investigate the effect of Roxadustat on inflammatory and lipid metabolism markers in patients with renal anemia.

Methods

This retrospective observational study enrolled a total of 52 patients with anemia secondary to CKD, who were categorized into a roxadustat group and a control group based on whether they received roxadustat treatment. The following markers, including hemoglobin (Hb), β-C-terminal telopeptide of type I collagen (β-CTX), total type I procollagen intact N-terminal propeptide (tP1NP), parathyroid hormone (PTH), osteocalcin (OC), 25-hydroxyvitamin D (25-OHD), alkaline phosphatase (ALP), calcium (Ca), and phosphorus (P), C-reactive protein (CRP), Procalcitonin (PCT), total cholesterol (TC), low-density lipoprotein (LDL), were measured before and after treatment. The changes of bone metabolism, inflammatory and lipid metabolism markers were compared before and after treatment.

Results

After a period of Roxadustat treatment, β-CTX and PTH levels were significantly lower compared to pre-treatment, while tP1NP, 25-OHD, and ALP levels increased compared to pre-treatment (P < 0.05). Inflammatory markers (PCT) and lipid metabolism markers (TC, LDL) were significantly reduced (P < 0.05). No statistically significant differences were observed in the control group.

Conclusion

In this study, Roxadustat treatment for renal anemia was associated with simultaneous improvements in markers of bone metabolism, inflammation, and lipid metabolism in CKD patients.